Soluble Urokinase Plasminogen Activator Receptor (suPAR) Concentrations are Elevated in Patients with Neuroendocrine Malignancies.
biomarker
neuroendocrine carcinoma
neuroendocrine tumor
soluble urokinase-type plasminogen activator receptor
survival
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
31 May 2020
31 May 2020
Historique:
received:
05
05
2020
revised:
18
05
2020
accepted:
25
05
2020
entrez:
4
6
2020
pubmed:
4
6
2020
medline:
4
6
2020
Statut:
epublish
Résumé
Neuroendocrine neoplasia (NEN) comprises heterogeneous tumors that are challenging to diagnose and, especially in cases of poorly differentiated (G3) NEN, are associated with very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options are urgently needed to improve the outcome of these patients. Recently, alterations of soluble urokinase-type plasminogen activator receptor (suPAR) serum levels were described in various types of cancers. However, the role of circulating suPAR as a biomarker in patients with NEN is unknown. In this study, we measured suPAR serum levels in a large and well-characterized cohort of 187 patients with NEN (neuroendocrine carcinomas (NEC)
Identifiants
pubmed: 32486367
pii: jcm9061647
doi: 10.3390/jcm9061647
pmc: PMC7355627
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Clin Lab. 2017 May 1;63(5):871-880
pubmed: 28627814
Histopathology. 2020 Jan;76(2):182-188
pubmed: 31433515
JHEP Rep. 2020 Jan 31;2(2):100080
pubmed: 32140677
Eur J Intern Med. 2017 Nov;45:46-50
pubmed: 28965741
Front Biosci (Landmark Ed). 2009 Jan 01;14:2494-503
pubmed: 19273214
Carcinogenesis. 2019 Aug 22;40(8):947-955
pubmed: 30805627
Expert Opin Pharmacother. 2020 Feb;21(2):183-191
pubmed: 31760823
Oncotarget. 2018 Jun 5;9(43):27027-27038
pubmed: 29930748
Surg Pathol Clin. 2019 Dec;12(4):1021-1044
pubmed: 31672292
N Engl J Med. 2020 Jan 30;382(5):470-472
pubmed: 31995696
J Intensive Care. 2019 Apr 27;7:26
pubmed: 31061709
Anticancer Drugs. 2001 Jun;12(5):387-400
pubmed: 11395568
Hepatology. 2011 Jan;53(1):209-18
pubmed: 20890893
Sci Rep. 2016 Dec 19;6:39481
pubmed: 27991579
N Engl J Med. 2020 Jan 30;382(5):416-426
pubmed: 31995687
Ann Oncol. 2013 Jan;24(1):152-60
pubmed: 22967994
Ann Surg Oncol. 2018 Aug;25(8):2467-2474
pubmed: 29789972
Neuroendocrinology. 2017 Feb 11;105(3):196-200
pubmed: 28190015
Int J Mol Sci. 2016 Jan 09;17(1):
pubmed: 26761003
Dis Markers. 2019 Oct 20;2019:5603474
pubmed: 31772690
World J Gastroenterol. 2016 Dec 7;22(45):9944-9953
pubmed: 28018101
Z Gastroenterol. 2018 Jun;56(6):583-681
pubmed: 29890561
APMIS. 1999 Jan;107(1):160-7
pubmed: 10190293
BMC Med. 2012 Jan 05;10:2
pubmed: 22221662
Digestion. 2017;95(2):109-114
pubmed: 28161703
Neuroendocrinology. 2018;107(4):375-386
pubmed: 30300897
Cancers (Basel). 2020 Mar 30;12(4):
pubmed: 32235636
Diabetes Obes Metab. 2017 Jun;19(6):901-905
pubmed: 28105731
Nat Rev Clin Oncol. 2019 Mar;16(3):149-150
pubmed: 30390038
Liver Int. 2014 Oct;34(9):1330-9
pubmed: 24575897
J Surg Oncol. 2018 Sep;118(3):416-421
pubmed: 30259518
Indian J Med Res. 2017 Mar;145(3):327-333
pubmed: 28749394
Recent Results Cancer Res. 2003;162:3-14
pubmed: 12790317
Ann Surg Oncol. 2020 May;27(5):1348-1355
pubmed: 31720931
Curr Treat Options Oncol. 2019 Aug 19;20(9):74
pubmed: 31428952
Int J Cancer. 2009 Apr 15;124(8):1860-70
pubmed: 19123477
Acta Oncol. 2014 Oct;53(10):1284-97
pubmed: 25140861